Marinus Pharmaceuticals, Inc. Class Action Lawsuit - MRNS
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Marinus Pharmaceuticals class action lawsuit seeks to represent purchasers or acquirers of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) publicly traded securities between March 17, 2021 and May 7, 2024, inclusive (the “Class Period”). Captioned Bishins v. Marinus Pharmaceuticals, Inc., No. 24-cv-02430 (E.D. Pa.), the Marinus Pharmaceuticals class action lawsuit charges Marinus Pharmaceuticals and certain of Marinus Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Marinus Pharmaceuticals class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Marinus Pharmaceuticals class action lawsuit must be filed with the court no later than August 5, 2024.
CASE ALLEGATIONS: Marinus Pharmaceuticals describes itself as a “commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders.”
The Marinus Pharmaceuticals class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; and (ii) defendants did not disclose that a possible consequence of failing to meet the early-stopping criteria in the RAISE trial would be that Marinus Pharmaceuticals would stop the separate Phase 3 RAISE II trial.
The Marinus Pharmaceuticals class action lawsuit further alleges that on April 15, 2024, Marinus Pharmaceuticals revealed that the RAISE trial had not met early stopping criteria and also that Marinus Pharmaceuticals would implement cost-saving measures. On this news, the price of Marinus Pharmaceuticals stock fell more than 84% over two trading sessions, according to the complaint.
Then, on May 8, 2024, the Marinus Pharmaceuticals class action lawsuit further alleges that Marinus Pharmaceuticals announced it would “stop[] clinical trial enrollment in the RAISE and RAISE II trials” and reduce Marinus Pharmaceuticals’ “workforce by approximately 20%.” On this news, the price of Marinus Pharmaceuticals stock fell nearly 9%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Marinus Pharmaceuticals publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Marinus Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Marinus Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Marinus Pharmaceuticals class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Marinus Pharmaceuticals class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.